Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) versus chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC).